Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M. Shema E, et al. Among authors: yarden y. Genes Dev. 2008 Oct 1;22(19):2664-76. doi: 10.1101/gad.1703008. Genes Dev. 2008. PMID: 18832071 Free PMC article.
Corrigendum: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M. Shema E, et al. Among authors: yarden y. Genes Dev. 2017 Sep 15;31(18):1926. doi: 10.1101/gad.307207.117. Genes Dev. 2017. PMID: 29051390 Free PMC article. No abstract available.
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
Pradeep C-, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y. Pradeep C-, et al. Among authors: yarden y. Oncogene. 2024 Apr;43(17):1317. doi: 10.1038/s41388-024-02990-w. Oncogene. 2024. PMID: 38418546 No abstract available.
Tuft cells and fibroblasts promote thymus regeneration through ILC2-mediated type 2 immune response.
Nevo S, Frenkel N, Kadouri N, Gome T, Rosenthal N, Givony T, Avin A, Peligero Cruz C, Kedmi M, Lindzen M, Ben Dor S, Damari G, Porat Z, Haffner-Krausz R, Keren-Shaul H, Yarden Y, Munitz A, Leshkowitz D, Goldfarb Y, Abramson J. Nevo S, et al. Among authors: yarden y. Sci Immunol. 2024 Jan 12;9(91):eabq6930. doi: 10.1126/sciimmunol.abq6930. Epub 2024 Jan 12. Sci Immunol. 2024. PMID: 38215193
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y. Marrocco I, et al. Among authors: yarden y. Cell Rep Med. 2023 Aug 15;4(8):101142. doi: 10.1016/j.xcrm.2023.101142. Epub 2023 Aug 8. Cell Rep Med. 2023. PMID: 37557179 Free PMC article.
Computational optimization of antibody humanness and stability by systematic energy-based ranking.
Tennenhouse A, Khmelnitsky L, Khalaila R, Yeshaya N, Noronha A, Lindzen M, Makowski EK, Zaretsky I, Sirkis YF, Galon-Wolfenson Y, Tessier PM, Abramson J, Yarden Y, Fass D, Fleishman SJ. Tennenhouse A, et al. Among authors: yarden y. Nat Biomed Eng. 2024 Jan;8(1):30-44. doi: 10.1038/s41551-023-01079-1. Epub 2023 Aug 7. Nat Biomed Eng. 2024. PMID: 37550425
351 results